1. 803 Phase 1/2 study using ENB-003, a first-in-class selective ETBRi, in combination with pembrolizumab in subjects with advanced refractory solid tumors. (10th December 2020) Authors: Jamal, Sumayah; Nagrial, Adnan; Joshua, Anthony; Eek, Richard; Jamal, Sumayah Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A480 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Endothelin-1 in the tumor microenvironment correlates with melanoma invasion. Issue 3 (June 2016) Authors: Chiriboga, Luis; Meehan, Shane; Osman, Iman; Glick, Michael; de la Cruz, Gelo; Howell, Brittny S.; Friedman-Jiménez, George; Schneider, Robert J.; Jamal, Sumayah Journal: Melanoma research Issue: Volume 26:Issue 3(2016) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗